Theracurmin (Nano-Curcumin) for Parkinson's Disease
Also known as: Nano-curcumin, Highly bioavailable curcumin
Enhanced curcumin bioavailability may enable anti-inflammatory and anti-aggregation effects in PD brain.
Mechanism of Action
Theracurmin delivers curcumin to inhibit α-synuclein aggregation, reduce microglial NF-κB activation, and activate Nrf2 in dopaminergic neurons — all limited by standard curcumin's poor bioavailability.
General mechanism: Nano-encapsulated curcumin with 27x bioavailability. NF-κB inhibitor, anti-amyloid, anti-tau, Nrf2 activator at achievable tissue levels.
Current Evidence
Preclinical evidence for curcumin in PD is strong but clinical translation limited by bioavailability. Theracurmin may resolve this limitation. No PD-specific Theracurmin trials.
Clinical Status: No PD trials with Theracurmin. AD bioavailability data informs potential.
Safety Profile
Safe. Well-tolerated in clinical trials. Same safety profile as standard curcumin with enhanced absorption.
Key Research Questions
- Can Theracurmin achieve CNS levels for α-synuclein inhibition?
- Would Theracurmin outperform standard curcumin supplements for PD?